2 ratings / 4.5 average

Non-Hodgkin Lymphoma

Fitoussi O, Belhadj K, Mounier N et al.

Hôpital Saint Louis, Paris, France.

 Haematologica 2011;96:1136–43.

Editor’s note: Although immunochemo-therapy with rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is the standard of care for patients with diffuse large B cell lymphoma (DLBCL), a significant proportion of patients with high-risk disease are not cured with this approach. There remains a lack of consensus as to the benefit of initial treatment intensification, particularly with regard to the role of high-dose therapy and autologous stem cell transplantation (ASCT) in first response.

Return to top

LATEST ARTICLES